Inserm, U930, Tours, France; Université François-Rabelais de Tours, UMR-U930, Tours, France.
Nucl Med Biol. 2014 Jan;41(1):106-13. doi: 10.1016/j.nucmedbio.2013.09.007. Epub 2013 Oct 8.
We examined whether [(18)F]LBT-999 ((E)-N-(4-fluorobut-2-enyl)2β-carbomethoxy-3β-(4'-tolyl)nortropane) is an efficient positron emission tomography (PET) tracer for the quantification of the dopamine transporter (DAT) in the healthy rat brain.
PET studies were performed using several experimental designs, i.e. test-retest, co-injection with different doses of unlabelled LBT, displacement with GBR12909 and pre-injection of amphetamine.
The uptake of [(18)F]LBT-999 confirmed its specific binding to the DAT. The non-displaceable uptake (BP(ND)) in the striatum, between 5.37 and 4.39, was highly reproducible and reliable, and was decreased by 90% by acute injection of GBR12909. In the substantia nigra/ventral tegmental area (SN/VTA), the variability was higher and the reliability was lower. Pre-injection of amphetamine induced decrease of [(18)F]LBT-999 BP(ND) of 50% in the striatum.
[(18)F]LBT-999 allows the quantification of the DAT in living rat brain with high reproducibility, sensitivity and specificity. It could be used to quantify the DAT in rodent models, thereby allowing to study neurodegenerative and neuropsychiatric diseases.
我们研究了 [(18)F]LBT-999((E)-N-(4-氟丁-2-烯基)-2β-羧甲基-3β-(4'-甲苯基)去甲托烷)是否是一种有效的正电子发射断层扫描 (PET) 示踪剂,用于定量健康大鼠脑内的多巴胺转运体 (DAT)。
使用多种实验设计进行 PET 研究,即测试-重测、与不同剂量未标记 LBT 共注射、用 GBR12909 置换和预先注射安非他命。
[(18)F]LBT-999 的摄取证实其与 DAT 特异性结合。纹状体中的非置换摄取 (BP(ND))在 5.37 到 4.39 之间,高度重现且可靠,并在急性注射 GBR12909 后降低 90%。在黑质/腹侧被盖区 (SN/VTA),变异性更高,可靠性更低。预先注射安非他命可使纹状体中 [(18)F]LBT-999 BP(ND) 降低 50%。
[(18)F]LBT-999 可用于定量活体大鼠脑内的 DAT,具有高重现性、灵敏度和特异性。它可用于定量啮齿动物模型中的 DAT,从而可用于研究神经退行性和神经精神疾病。